Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALDX |
---|---|---|
09:32 ET | 6237 | 3.77 |
09:34 ET | 2098 | 3.76 |
09:36 ET | 520 | 3.77 |
09:38 ET | 1760 | 3.78 |
09:41 ET | 100 | 3.81 |
09:43 ET | 500 | 3.79 |
09:45 ET | 100 | 3.79 |
09:48 ET | 246 | 3.79 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Aldeyra Therapeutics Inc | 225.2M | -7.5x | --- |
Pyxis Oncology Inc | 225.0M | -2.7x | --- |
Merrimack Pharmaceuticals Inc | 223.7M | -0.3x | --- |
Design Therapeutics Inc | 227.7M | -4.0x | --- |
Prelude Therapeutics Inc | 221.9M | -2.1x | --- |
Eliem Therapeutics Inc | 216.4M | -13.7x | --- |
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $225.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.38 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -7.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.